好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Interim analysis II from REAL Study: Quality of life and persistence with fingolimod treatment in relapsing remitting multiple sclerosis patients in Argentina
Multiple Sclerosis
(-)
255
Authors/Disclosures
Gaston A. Kuperman, PhD
PRESENTER 		No disclosure on file
Dawn W. Langdon, PhD (Royal Holloway) Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Prof. Langdon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Prof. Langdon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Prof. Langdon has received research support from Merck. The institution of Prof. Langdon has received research support from Novartis. The institution of Prof. Langdon has received research support from MS Society (UK). The institution of Prof. Langdon has received research support from Multiple Sclerosis Trust (UK).